A well-known aggressive investor recently made bold remarks at her New York office: over the next three years, the U.S. economic policy environment may trigger a new growth cycle, and the stock market is expected to enter a new upward phase.

Her flagship fund has performed remarkably well over the past year—an increase of 35.5%, nearly twice the gains of mainstream indices. Achieving this was no easy feat. Just a year ago, this investor was controversial and mocked by the market for her aggressive decisions. But the market in 2025 has vindicated her with actual returns.

Her investment logic has remained consistent: take profits when appropriate, then go all-in on the next hot sector. As 2026 approaches, her actions are quite representative—large-scale, strategic positioning in the biotech sector, especially in gene editing and genomics. She has investments across the main players in this emerging industry chain.

This reflects an interesting phenomenon: when macro policy environments change, aggressive capital begins to sense new opportunities. Deregulation, tax cuts, and a stable monetary policy framework create conditions that attract funds to long-term, high-risk, high-potential sectors. Gene editing is precisely such a track—full of promise but requiring capital patience to see it through.

Interestingly, while heavily invested in technological innovation, she has not completely abandoned other allocations. This shows that even aggressive investors are learning how to balance risk and opportunity.